Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2017 | Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib | CHAO-CHI HO ; WEI-YU LIAO ; Lin C.-A.; JIN-YUAN SHIH ; CHONG-JEN YU ; Chih-Hsin CHIH-HSIN YANG | Journal of Thoracic Oncology | 179 | 164 | |
2005 | Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R | Gow C.-H.; JIN-YUAN SHIH ; YIH-LEONG CHANG ; CHONG-JEN YU | PLoS Medicine | 25 | 0 | |
2019 | Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer | Liu Y.-N.; Tsai M.-F.; SHANG-GIN WU ; Chang T.-H.; TZU-HSIU TSAI ; Gow C.-H.; YIH-LEONG CHANG ; JIN-YUAN SHIH | International Journal of Cancer | 34 | 34 | |
2007 | Acrometastasis from squamous cell lung cancer | Lai C.-C.; Tan C.-K.; JIN-YUAN SHIH | CMAJ | 4 | 0 | |
2018 | Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program | Peters, Solange; Curioni-Fontecedro, Alessandra; Nechushtan, Hovav; JIN-YUAN SHIH ; WEI-YU LIAO ; Gautschi, Oliver; Spataro, Vito; Unk, Mojca; CHIH-HSIN YANG ; Lorence, Robert M; Carrière, Philippe; Cseh, Agnieszka; Chang, Gee-Chen | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 66 | 57 | |
2012 | Advanced non-small cell lung cancer in patients aged 45 years or younger: Outcomes and prognostic factors | CHIA-LIN HSU ; KUAN-YU CHEN ; JIN-YUAN SHIH ; CHAO-CHI HO ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | BMC Cancer | 72 | 66 | |
2015 | Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis | CHIA-LIN HSU ; JEN-HAU CHEN ; KUAN-YU CHEN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | Journal of Geriatric Oncology | 35 | 34 | |
2021 | Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence | Lu S.; JIN-YUAN SHIH ; Jang T.-W.; Liam C.-K.; Yu Y. | Advances in Therapy | 12 | 9 | |
2012 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial | CHIH-HSIN YANG ; JIN-YUAN SHIH ; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU ; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG ; Miller V.A. | The Lancet Oncology | 385 | 337 | |
2019 | Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations | SHENG-KAI LIANG ; JEN-CHUNG KO ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Lung Cancer | 27 | 25 | |
2013 | ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors | Huang C.-P.; Tsai M.-F.; Chang T.-H.; Tang W.-C.; Chen S.-Y.; Lai H.-H.; Lin T.-Y.; CHIH-HSIN YANG ; PAN-CHYR YANG ; JIN-YUAN SHIH ; Lin S.-B. | Cancer Letters | 115 | 109 | |
2024 | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study | Passaro, A; Wang J.; Wang, Y; Lee, S-H; Melosky, B; JIN-YUAN SHIH ; Azuma, K; Juan-Vidal, O; Cobo, M; Felip, E; Girard, N; Cortot, A B; Califano, R; Cappuzzo, F; Owen, S; Popat, S; Tan, J-L; Salinas, J; Tomasini, P; Gentzler, R D; William, W N; Reckamp, K L; Takahashi, T; Ganguly, S; Kowalski, D M; Bearz, A; MacKean, M; Barala, P; Bourla, A B; Girvin, A; Greger, J; Millington, D; Withelder, M; Xie, J; Sun, T; Shah, S; Diorio, B; Knoblauch, R E; Bauml, J M; Campelo, R G; Cho, B C | Annals of oncology : official journal of the European Society for Medical Oncology | 17 | | |
2016 | Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review | YEN-TING LIN ; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Clinical Lung Cancer | 26 | 23 | |
2018 | Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting | Reck M.; Garassino M.C.; Imbimbo M.; Shepherd F.A.; Socinski M.A.; JIN-YUAN SHIH ; Tsao A.; Lee P.; Winfree K.B.; Sashegyi A.; Cheng R.; Varea R.; Levy B.; Garon E. | Lung Cancer | 28 | 25 | |
2021 | Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer | YU-SEN HUANG ; JENNY LING-YU CHEN ; HSIN-MING CHEN ; Yeh, Li-Hao; JIN-YUAN SHIH ; RUOH-FANG YEN ; YEUN-CHUNG CHANG | BMC cancer | 5 | 3 | |
2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 55 | 49 | |
2016 | Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma | SHANG-GIN WU ; Liu Y.-N.; CHONG-JEN YU ; PAN-CHYR YANG ; JIN-YUAN SHIH | JAMA Oncology | 20 | 16 | |
2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 15 | 15 | |
2023 | Association of pulmonary nontuberculous mycobacteria with the outcomes of patients with lung cancer: A retrospective matched cohort study with a special emphasis on the impact of chemotherapy | TING-YU LIAO ; JANN-YUAN WANG ; JIN-YUAN SHIH | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi | 0 | 1 | |
2017 | Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression | CHUNG-YU CHEN ; Chen Y.-Y.; Chen J.J.W.; KUAN-YU CHEN ; CHAO-CHI HO ; JIN-YUAN SHIH ; YIH-LEONG CHANG ; CHONG-JEN YU ; PAN-CHYR YANG | Oncotarget | 9 | 9 | |